BioNTech (BNTX) PT Raised to Street High $240 at Canaccord Genuity as Vaccine Dollars Fuel Growth Initiatives
Tweet Send to a Friend
Canaccord Genuity analyst Arlinda Lee raised the price target on BioNTech (NASDAQ: BNTX) to a Street High $240.00 (from $130.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
